
Ticker Take
Jon Erlichman
Investing doesn’t have to be boring or confusing. Accomplished business broadcaster Jon Erlichman and entertainment media veteran Caroline Lesley break down the stock market and the forces reshaping it, including AI, in plain English. From the floor of the New York Stock Exchange to interviews with the world’s top investors on how they think and where they see opportunity, Ticker Take makes finance clear, useful and entertaining, whether you’re just learning what a ticker is or you’ve been in the market for decades. Tune in and learn to invest like a pro.
The AI Boom Isn't Over: 7 Stocks to Own Now
Episode discussion: Jim Thorne argues AI capex boom lasts until 2031, recommending NVDA, MU, MSFT, CRWD, PLTR, SPCX
Speakers’ claims: Host and guest Jim Thorne of Wellington-Altus discuss whether the AI investment cycle is over, with Thorne arguing it has years left to run. Thorne characterizes the current AI phase as the 'MS-DOS era' and predicts the capital expenditure boom will continue until 2031 due to the expiration of 100% tax deductibility for capital expenditures in the US. He advises investors to focus on companies with wide moats, access to credit markets, and strong free cash flow, dismissing negative 'doomer' narratives. The episode highlights six stocks: Nvidia, Micron, Microsoft, CrowdStrike, Palantir, and SpaceX, positioning them as leaders in AI infrastructure, memory, enterprise software, cybersecurity, implementation, and aerospace respectively.
6 Biotech Stocks for a Volatile Bull Market
Episode discussion: Guest Eden Raheem highlights six biotech stocks, favoring value plays over overvalued AI narratives.
Speakers’ claims: Eden Raheem of Next Edge Capital argues biotech is entering a new bull market, driven by rate sensitivity and long-duration cash flows. He identifies six specific stocks, including Cytokinetics, Legend Biotech, TG Therapeutics, Alpha Cognition, ClearPoint Neuro, and Nectar Therapeutics, citing specific valuation gaps and clinical data. Conversely, he advises against buying Moderna, citing overvaluation and limited market size despite recent AI-driven rallies. The discussion emphasizes the sector's sensitivity to interest rates and the importance of comparing public valuations to recent private M&A transactions.